MX2017009294A - Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. - Google Patents

Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.

Info

Publication number
MX2017009294A
MX2017009294A MX2017009294A MX2017009294A MX2017009294A MX 2017009294 A MX2017009294 A MX 2017009294A MX 2017009294 A MX2017009294 A MX 2017009294A MX 2017009294 A MX2017009294 A MX 2017009294A MX 2017009294 A MX2017009294 A MX 2017009294A
Authority
MX
Mexico
Prior art keywords
lixisenatide
treatment
diabetes mellitus
mellitus patients
pediatric type
Prior art date
Application number
MX2017009294A
Other languages
English (en)
Other versions
MX381944B (es
Inventor
JAN Christelle
Bergmann Karin
Hincelin-Méry Agnès
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52354814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2017009294A publication Critical patent/MX2017009294A/es
Publication of MX381944B publication Critical patent/MX381944B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a Iixisenatida para uso en pacientes pediátricos.
MX2017009294A 2015-01-16 2016-01-15 Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos. MX381944B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15151488 2015-01-16
PCT/EP2016/050804 WO2016113404A1 (en) 2015-01-16 2016-01-15 Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide

Publications (2)

Publication Number Publication Date
MX2017009294A true MX2017009294A (es) 2017-11-20
MX381944B MX381944B (es) 2025-03-13

Family

ID=52354814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009294A MX381944B (es) 2015-01-16 2016-01-15 Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.

Country Status (21)

Country Link
US (4) US20160235818A1 (es)
EP (1) EP3244912B1 (es)
JP (1) JP7274258B2 (es)
KR (1) KR102614574B1 (es)
CN (1) CN107405386A (es)
AR (1) AR103415A1 (es)
AU (1) AU2016207964B2 (es)
CL (1) CL2017001843A1 (es)
CR (1) CR20170376A (es)
EA (1) EA035423B1 (es)
ES (1) ES2895513T3 (es)
IL (1) IL253460B (es)
MX (1) MX381944B (es)
PH (1) PH12017501290A1 (es)
PL (1) PL3244912T3 (es)
PT (1) PT3244912T (es)
SG (1) SG11201705755UA (es)
TN (1) TN2017000292A1 (es)
TW (1) TWI706779B (es)
WO (1) WO2016113404A1 (es)
ZA (1) ZA201704512B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray
WO2022221177A1 (en) * 2021-04-11 2022-10-20 Khurana Vikas Diagnosis and treatment of congestive colon failure (ccf)
WO2024133412A1 (en) 2022-12-21 2024-06-27 Novo Nordisk A/S Methods and systems for estimating fbg value from cgm data

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
EP2435061A4 (en) * 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
HUE026489T2 (en) * 2009-11-13 2016-06-28 Sanofi Aventis Deutschland Combination of lixisenatide and metformin to treat type 2 diabetes
CN103841988A (zh) 2011-05-13 2014-06-04 赛诺菲-安万特德国有限公司 用于治疗2型糖尿病患者的利西拉来和二甲双胍
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
CN108079281A (zh) * 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
BR112014010200A2 (pt) * 2011-10-28 2020-10-27 Sanofi-Aventis Deutschland Gmbh combinação farmacêutica, bem como seu uso na preparação de um medicamento para o tratamento de diabetes tipo 2

Also Published As

Publication number Publication date
EA201791611A1 (ru) 2017-11-30
US20160235818A1 (en) 2016-08-18
AU2016207964B2 (en) 2021-10-14
PH12017501290A1 (en) 2018-02-05
WO2016113404A1 (en) 2016-07-21
US20190365864A1 (en) 2019-12-05
ZA201704512B (en) 2019-07-31
TWI706779B (zh) 2020-10-11
IL253460A0 (en) 2017-09-28
EP3244912B1 (en) 2021-08-18
AR103415A1 (es) 2017-05-10
KR20170102550A (ko) 2017-09-11
IL253460B (en) 2022-06-01
PT3244912T (pt) 2021-10-27
SG11201705755UA (en) 2017-08-30
CA2973632A1 (en) 2016-07-21
US20240173384A1 (en) 2024-05-30
CR20170376A (es) 2017-09-25
CN107405386A (zh) 2017-11-28
ES2895513T3 (es) 2022-02-21
NZ734595A (en) 2022-03-25
BR112017015099A2 (pt) 2018-04-17
JP7274258B2 (ja) 2023-05-16
CL2017001843A1 (es) 2018-02-23
MX381944B (es) 2025-03-13
TN2017000292A1 (en) 2019-01-16
EA035423B1 (ru) 2020-06-11
TW201639551A (zh) 2016-11-16
JP2018503644A (ja) 2018-02-08
KR102614574B1 (ko) 2023-12-18
EP3244912A1 (en) 2017-11-22
AU2016207964A1 (en) 2017-08-31
PL3244912T3 (pl) 2021-12-20
US20210187075A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
CY1120030T1 (el) Διπλοι glp1/gip ή τριγωνικοι αγωνιστες glp1/gip/ γλυκαγονης
AR091422A1 (es) Analogos peptidicos de la exendina 4
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CR20190313A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
PT3681872T (pt) Beta-hidroxietilaminas substituídas com heteroarilo para utilização no tratamento de hiperglicemia
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
IL254496A0 (en) Treatment of type 2 diabetes patients
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
MX2015017136A (es) Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
RU2014151103A (ru) Применение соединений класса 1,3,4-тиадиазина и их фармацевтической композиции с аскорбиновой кислотой в качестве средства коррекции экспериментального аллоксанового сахарного диабета
AR103944A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
BR112016029044A2 (pt) ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite
HK1239556A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide